Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury — VialBase Research

Summary

This study evaluated topical thymosin beta-4 for corneal wound healing after alkali injury in a mouse model. Tβ4 treatment accelerated healing, reduced inflammation, and decreased inflammatory cytokine levels, supporting both wound-healing and anti-inflammatory mechanisms.

Key Findings

• Topical Tβ4 significantly accelerated corneal re-epithelialization after alkali burn
• Reduced inflammatory cell infiltration (polymorphonuclear cells)
• Decreased inflammatory cytokines (TNF-α, IL-1β, MIP-2) in the cornea
• Dual mechanism: promotes healing while simultaneously reducing inflammation
• Effects observed with topical application (eye drops)
• Led to subsequent clinical development for corneal healing (RGN-259)

Methodology

Mouse corneal alkali burn model. Eyes treated with topical Tβ4 drops vs saline control multiple times daily. Outcomes assessed via slit-lamp examination, histology, and cytokine measurement (ELISA) at multiple time points over 2 weeks.

Limitations

• Mouse corneal model — corneal healing dynamics differ from musculoskeletal tissue
• Full-length Tβ4 used, not TB-500 fragment
• Small animal study
• Topical application route — different from injectable TB-500 use
• Corneal healing is a relatively simple wound model

Relevance to Content

Supports the anti-inflammatory + wound-healing dual narrative for TB-500. The corneal healing work led to clinical development (RGN-259), making it one of the few Tβ4 applications with a clinical pathway. Useful for content establishing the breadth of Tβ4/TB-500 healing evidence across tissue types.

See Also

• Parent compound: TB-500